Racial Disparities in Response to IBD Directed Therapy in Crohn’s Disease and Ulcerative Colitis: A Single Center Experience
Year: 2025
Type: article
Study design: Observational Study
Abstract: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) associated with significant morbidity and mortality. Current clinical guidelines recommend a range of therapies, including tumor necrosis factor alpha (TNFα) antagonists, anti-integrins, interleukin-12/23 (IL12/23) inhibitors, Janus kinase (JAK) inhibitors, and/or corticosteroids for both induction and maintenance of remission. Determining the optimal medication for individual patients can be challenging due to the complexity of treatment options and the need to consider numerous phenotypic factors. While treatment guidelines do not address racial differences explicitly, prior research has highlighted significant phenotypic disparities based on race. This study aims to explore the racial disparities in treatment outcomes and medication selection between Caucasian and African American patients with UC or CD treated with IBD-directed therapies.
Source: The Medicine Forum
Authors: Ananya Venkatesh, Justin Robbins, Zach Breslin, Cuckoo Choudhary
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4411402890